JF
ZVRA icon

Jump Financial’s Zevra Therapeutics ZVRA Stock Holding History

Jump Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,232
Closed -$59.3K – 2349
2024
Q1 		$59.3K Sell
10,232
-22,968
-69% -$141K ﹤0.01% 1825
2023
Q4 		$217K Buy
+33,200
New +$155K 0.01% 1520
2023
Q2 		– Sell
-19,317
Closed -$106K – 2229
2023
Q1 		$106K Buy
19,317
+1,551
+9% +$8.21K ﹤0.01% 1432
2022
Q4 		$81.5K Buy
+17,766
New +$90.2K ﹤0.01% 1452
2022
Q3 		– Sell
-32,939
Closed -$147K – 2040
2022
Q2 		$147K Buy
+32,939
New +$150K 0.01% 1373

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Jump Financial's ZVRA Position: Q2 2024 in Review

Jump Financial sold out of Zevra Therapeutics (ZVRA) in Q2 2024, closing a stake of 10,232 shares — an estimated $59.3K sold.

Jump Financial first reported a position in ZVRA in Q2 2022 and held it in 5 quarters. The position peaked at $217K in Q4 2023. 93 funds tracked by Wall St. Rank hold ZVRA as of Q2 2024.

  • Jump Financial reported no remaining Zevra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jump Financial sold 10,232 Zevra Therapeutics shares in Q2 2024, an estimated $59.3K.
  • Jump Financial first reported a position in Zevra Therapeutics in Q2 2022 and held it in 5 quarters.
  • Jump Financial's Zevra Therapeutics position peaked at $217K in Q4 2023.
  • 93 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2024.

Based on Jump Financial's 13F filing for Q2 2024, filed 14 Aug 2024.